231 related articles for article (PubMed ID: 29359984)
1. Current approaches for identifying high-risk non-muscle invasive bladder cancer.
Sanli O; Lotan Y
Expert Rev Anticancer Ther; 2018 Mar; 18(3):223-235. PubMed ID: 29359984
[TBL] [Abstract][Full Text] [Related]
2. Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendations.
Kassouf W; Traboulsi SL; Schmitz-Dräger B; Palou J; Witjes JA; van Rhijn BW; Grossman HB; Kiemeney LA; Goebell PJ; Kamat AM
Urol Oncol; 2016 Oct; 34(10):460-8. PubMed ID: 27368880
[TBL] [Abstract][Full Text] [Related]
3. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data.
Burger M; Grossman HB; Droller M; Schmidbauer J; Hermann G; Drăgoescu O; Ray E; Fradet Y; Karl A; Burgués JP; Witjes JA; Stenzl A; Jichlinski P; Jocham D
Eur Urol; 2013 Nov; 64(5):846-54. PubMed ID: 23602406
[TBL] [Abstract][Full Text] [Related]
4. Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations.
Witjes JA; Babjuk M; Gontero P; Jacqmin D; Karl A; Kruck S; Mariappan P; Palou Redorta J; Stenzl A; van Velthoven R; Zaak D
Eur Urol; 2014 Nov; 66(5):863-71. PubMed ID: 25001887
[TBL] [Abstract][Full Text] [Related]
5. The role of urine markers, white light cystoscopy and fluorescence cystoscopy in recurrence, progression and follow-up of non-muscle invasive bladder cancer.
Karaoglu I; van der Heijden AG; Witjes JA
World J Urol; 2014 Jun; 32(3):651-9. PubMed ID: 24166285
[TBL] [Abstract][Full Text] [Related]
6. Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)?
Geavlete B; Multescu R; Georgescu D; Jecu M; Stanescu F; Geavlete P
BJU Int; 2012 Feb; 109(4):549-56. PubMed ID: 21711438
[TBL] [Abstract][Full Text] [Related]
7. Early bladder cancer: concept, diagnosis, and management.
Kitamura H; Tsukamoto T
Int J Clin Oncol; 2006 Feb; 11(1):28-37. PubMed ID: 16508726
[TBL] [Abstract][Full Text] [Related]
8. Innovations in the endoscopic management of bladder cancer: is the era of white light cystoscopy over.
Soria F; Gurioli A; Peraldo F; Oderda M; Giona S; Ambrosini E; Frea B; Gontero P
Urologia; 2013 Jun; 80 Spec No 1():1-8. PubMed ID: 23813287
[TBL] [Abstract][Full Text] [Related]
9. Optimised photodynamic diagnosis for transurethral resection of the bladder (TURB) in German clinical practice: results of the noninterventional study OPTIC III.
Bach T; Bastian PJ; Blana A; Kaminsky A; Keller S; Knoll T; Lang C; Promnitz S; Ubrig B; Keller T; Qvick B; Burger M;
World J Urol; 2017 May; 35(5):737-744. PubMed ID: 27578233
[TBL] [Abstract][Full Text] [Related]
10. Prognostic relevance of positive urine markers in patients with negative cystoscopy during surveillance of bladder cancer.
Todenhöfer T; Hennenlotter J; Guttenberg P; Mohrhardt S; Kuehs U; Esser M; Aufderklamm S; Bier S; Harland N; Rausch S; Gakis G; Stenzl A; Schwentner C
BMC Cancer; 2015 Mar; 15():155. PubMed ID: 25884545
[TBL] [Abstract][Full Text] [Related]
11. Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature.
Rink M; Babjuk M; Catto JW; Jichlinski P; Shariat SF; Stenzl A; Stepp H; Zaak D; Witjes JA
Eur Urol; 2013 Oct; 64(4):624-38. PubMed ID: 23906669
[TBL] [Abstract][Full Text] [Related]
12. Can urinary biomarkers replace cystoscopy?
Maas M; Bedke J; Stenzl A; Todenhöfer T
World J Urol; 2019 Sep; 37(9):1741-1749. PubMed ID: 30283995
[TBL] [Abstract][Full Text] [Related]
13. Blue light cystoscopy for detection and treatment of non-muscle invasive bladder cancer.
Mark JR; Gelpi-Hammerschmidt F; Trabulsi EJ; Gomella LG
Can J Urol; 2012 Apr; 19(2):6227-31. PubMed ID: 22512972
[TBL] [Abstract][Full Text] [Related]
14. Urinary markers in the everyday diagnosis of bladder cancer.
Dal Moro F; Valotto C; Guttilla A; Zattoni F
Urologia; 2013; 80(4):265-75. PubMed ID: 24419920
[TBL] [Abstract][Full Text] [Related]
15. [Non-muscle invasive bladder cancer].
Irani J
Rev Prat; 2014 Dec; 64(10):1382-5. PubMed ID: 25665317
[TBL] [Abstract][Full Text] [Related]
16. Clinical Decision Making in Surveillance of Non-Muscle-Invasive Bladder Cancer: The Evolving Roles of Urinary Cytology and Molecular Markers.
Zuiverloon TCM; de Jong FC; Theodorescu D
Oncology (Williston Park); 2017 Dec; 31(12):855-62. PubMed ID: 29297169
[TBL] [Abstract][Full Text] [Related]
17. [The clinical value of fluorescence cystoscopy in the detection of superficial transitional epithelial cell carcinoma of the bladder].
Jichlinski P; Wagniéres G; Forrer M; Mizeret J; Guillou L; Schmidlin F; Graber P; Van den Bergh H; Leisinger HJ
Ann Urol (Paris); 1997; 31(1):43-8. PubMed ID: 9157821
[TBL] [Abstract][Full Text] [Related]
18. Follow-up procedures for non-muscle-invasive bladder cancer: an update.
Anastasiadis A; Cordeiro E; Bus MT; Alivizatos G; de la Rosette JJ; de Reijke TM
Expert Rev Anticancer Ther; 2012 Sep; 12(9):1229-41. PubMed ID: 23098122
[TBL] [Abstract][Full Text] [Related]
19. Urine Cytology Rarely Escalates Clinical Management in the Surveillance of Non-muscle-Invasive Bladder Cancer.
Feiertag N; Barry E; Abramson M; Park JY; Kovac E; Aboumohamed A; Watts K; Sankin A
Clin Genitourin Cancer; 2023 Apr; 21(2):258-264. PubMed ID: 36621462
[TBL] [Abstract][Full Text] [Related]
20. Budget impact of incorporating one instillation of hexaminolevulinate hydrochloride blue-light cytoscopy in transurethral bladder tumour resection for patients with non-muscle-invasive bladder cancer in Sweden.
Rose JB; Armstrong S; Hermann GG; Kjellberg J; Malmström PU
BJU Int; 2016 Jun; 117(6B):E102-13. PubMed ID: 26305667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
